Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ocrelizumab Impairs the Phenotype and Function of Memory CD8 + T Cells
Amandine Mathias, Vasiliki Pantazou, Sylvain Perriot, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 2
Open Access | Times Cited: 18

Showing 18 citing articles:

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
Carla Rodriguez-Mogeda, Zoë YGJ van Lierop, Susanne M. A. van der Pol, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 15
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
Aurora Zanghì, Giovanna Borriello, Simona Bonavita, et al.
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 4495-4502
Open Access | Times Cited: 3
Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience
Martina Nasello, Valeria Zancan, Virginia Rinaldi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5353-5353
Open Access | Times Cited: 3
Exploring the depths of IgG4: insights into autoimmunity and novel treatments
Selen Ünlü, Blanca G. Sánchez Navarro, Elif Çakan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis
Gianmarco Abbadessa, Maria Teresa Lepore, Sara Bruzzaniti, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 4
Open Access | Times Cited: 2
B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis
Can Ulutekin, Edoardo Galli, Bettina Schreiner, et al.
Cell Reports Medicine (2023) Vol. 5, Iss. 1, pp. 101351-101351
Open Access | Times Cited: 7
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides
Lara S. Dungan, Jean Dunne, Michael Savio, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 1
Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis
Sergey A. Kornilov, Nathan D. Price, Richard Gelinas, et al.
Journal of the Neurological Sciences (2024) Vol. 467, pp. 123303-123303
Closed Access | Times Cited: 1
Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy
Brit Ellen Rød, Stig Wergeland, Kjetil Bjørnevik, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105037-105037
Open Access | Times Cited: 4
Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review
Spyros Deftereos, George D. Vavougios, Christos Bakirtzis, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 7, pp. 536-551
Closed Access
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study
Christoph Friedli, Nik Krajnc, Helly Hammer, et al.
Journal of Central Nervous System Disease (2024) Vol. 16
Open Access
Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients
Smaranda Maier, Adina Huţanu, Laura Bărcuţean, et al.
Revista română de medicină de laborator (2024) Vol. 32, Iss. 3, pp. 245-254
Open Access
Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy
Mie Rye Wæde, Lasse F. Voss, Christina Kingo, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 10, pp. 2657-2672
Open Access
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis
Marco Vercellino, Stella Marasciulo, Emanuela Ricotti, et al.
Multiple Sclerosis Journal (2024)
Closed Access
The Role of CXCR3 in Nervous System‐Related Diseases
Fangyuan Wang, Bing Guo, Ziyang Jia, et al.
Mediators of Inflammation (2024) Vol. 2024, Iss. 1
Open Access
Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis
Fabiënne van Puijfelik, Katelijn M. Blok, Romy A. M. Klein Kranenbarg, et al.
Brain Communications (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 1
Can Natalizumab be Safely Used After Ocrelizumab in Treating Multiple Sclerosis?
Lana Zhovtis Ryerson, Susan Goelz, C. Riley
International Journal of Neuroscience and Research (2023) Vol. 3, Iss. 1, pp. 1-3
Open Access | Times Cited: 1
Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy
Griffith B. Perkins, Christopher M. Hope, Cheng Sheng Chai, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top